- Generic steroid based drugs corresponding to the therapeutic class of sex hormones and regulators of the gonadal function:
mainly including the progestins, estrogens and androgens group. They are mostly related to the field of women's health and associated with the following applications.
- Reproductive health: primarily focused on hormonal contraception using oral contraceptives; mini-pills (progestin only) and combined pills (combination of progestin and estrogen).
- Hormone therapies: treatment of menstrual cycle regulation, treatment of dysmenorrheal or other menstrual cycle abnormalities.
- Hormone replacement therapy: mainly focused on the palliation of symptoms and signs of menopause.
- Oncology treatments in hormone-dependent tumors such as the following cancers found in the breast, endometrium, uterus or prostate.
Ours products: 
This group makes up the core of Cyndea Pharma´s portfolio of products as well as establishes the company as a reference in generic drugs within the field of Women's Health and hormone-dependent cancer therapies.
- Generic steroid based drugs corresponding to the therapeutic class of adrenal corticosteroids:
Used in accordance with their anti-inflammatory properties. Depending on the way in which they are administered, they can be used for the treatment of various conditions such as: asthma, allergic rhinitis, for various eye treatments, skin treatments such as dermatitis, psoriasis, eczema, for various applications in rheumatology, trauma or for treatment of intestinal inflammation.
Together with the already established products in the market, most being in solid oral dosages (tablets in particular) there is a whole range of possibilities regarding the emergence of new products deriving from already existing highly active ones: new concentrations, combinations and new therapeutic applications related in many cases to the development of new forms of drug administration such as gels, transdermal patches, subcutaneous implants or vaginal rings. Cyndea Pharma addresses in its strategic development plan, the manufacturing and development of generic versions of all these new pharmaceutical forms as well as presentations that may arise which represent an improvement in the efficiency, safety, quality and adherence to these types of treatments.